Literature DB >> 23913711

Angelman syndrome in Denmark. birth incidence, genetic findings, and age at diagnosis.

Line Granild Bie Mertz1, Rikke Christensen, Ida Vogel, Jens Michael Hertz, Karen Brøndum Nielsen, Karen Grønskov, John R Østergaard.   

Abstract

Angelman syndrome (AS) is a neurogenetic disorder caused by loss of expression of the maternal imprinted gene UBE3A on chromosome 15q11.2-q13. Clinical features of AS include severe intellectual disability, a happy disposition, ataxia, mandibular prognatism, and epilepsy. Our objectives were to examine the birth incidence of AS in Denmark and to characterize the size of the 15q11.2-q13 deletions with 1,000K array CGH. In addition, we analyzed genotype differences in regard to age at diagnosis and investigated the occurrence of deletions/duplications outside the 15q11.2-q13 regions. We identified 51 patients with genetically verified AS, which corresponded to a birth incidence of 1:24,580 (95%CI: 1:23,727-1:25,433). Thirty-six patients showed a deletion; 13 had a Class I deletion and 20 had a Class II deletion. There was bimodal distribution of the BP3 breakpoint. Three patients had larger and atypical deletions, with distal breakpoints telomeric to BP3. Five patients had paternal uniparental disomy (pUPD) of chromosome 15, and four had a verified UBE3A mutation. Additional deletions/duplications outside the 15q11.2-q13 areas were demonstrated in half the participants. Six harbored more than one CNV. Mean age at diagnosis was 21 months (95%CI: 17-23 months) for children with a deletion and 46 months (95%CI: 36-55 months) for children with pUPD or a UBE3A mutation (P < 0.01). The presence of a CNV outside 15q11.2-q13 did not have an impact on age at diagnosis.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  15q11.2-q13; Angelman syndrome; array CGH; birth incidence; breakpoints; copy number variation; deletion

Mesh:

Year:  2013        PMID: 23913711     DOI: 10.1002/ajmg.a.36058

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  24 in total

Review 1.  Role of DNA methylation in imprinting disorders: an updated review.

Authors:  Amr Rafat Elhamamsy
Journal:  J Assist Reprod Genet       Date:  2017-03-09       Impact factor: 3.412

2.  Electrophysiological Phenotype in Angelman Syndrome Differs Between Genotypes.

Authors:  Joel Frohlich; Meghan T Miller; Lynne M Bird; Pilar Garces; Hannah Purtell; Marius C Hoener; Benjamin D Philpot; Michael S Sidorov; Wen-Hann Tan; Maria-Clemencia Hernandez; Alexander Rotenberg; Shafali S Jeste; Michelle Krishnan; Omar Khwaja; Joerg F Hipp
Journal:  Biol Psychiatry       Date:  2019-01-19       Impact factor: 13.382

3.  Motor Deficits Coupled to Cerebellar and Striatal Alterations in Ube3am-/p+ Mice Modelling Angelman Syndrome Are Attenuated by Adenosine A2A Receptor Blockade.

Authors:  Ana Moreira-de-Sá; Francisco Q Gonçalves; João P Lopes; Henrique B Silva; Ângelo R Tomé; Rodrigo A Cunha; Paula M Canas
Journal:  Mol Neurobiol       Date:  2021-01-19       Impact factor: 5.590

4.  Clinical Characterization of Epilepsy in Children With Angelman Syndrome.

Authors:  Daiana Cassater; Mariana Bustamante; Lisa Sach-Peltason; Alexander Rotenberg; Mark Nespeca; Wen-Hann Tan; Lynne M Bird; Joerg F Hipp
Journal:  Pediatr Neurol       Date:  2021-08-31       Impact factor: 3.372

5.  Incidence of Aicardi-Goutières syndrome and KCNT1-related epilepsy in Denmark.

Authors:  Rikke S Møller; Liwei Zhao; Jessica R Shoaff; Morten Duno; Brian Nauheimer Andersen; Viet Nguyen; Terry C Fang; Varant Kupelian; Robyn Thorén
Journal:  Mol Genet Metab Rep       Date:  2022-10-13

Review 6.  UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome.

Authors:  Ype Elgersma; Monica Sonzogni
Journal:  Dev Med Child Neurol       Date:  2021-02-04       Impact factor: 5.449

7.  Evaluating Sleep Disturbances in Children With Rare Genetic Neurodevelopmental Syndromes.

Authors:  Olivia J Veatch; Beth A Malow; Hye-Seung Lee; Aryn Knight; Judy O Barrish; Jeffrey L Neul; Jane B Lane; Steven A Skinner; Walter E Kaufmann; Jennifer L Miller; Daniel J Driscoll; Lynne M Bird; Merlin G Butler; Elisabeth M Dykens; June-Anne Gold; Virginia Kimonis; Carlos A Bacino; Wen-Hann Tan; Sanjeev V Kothare; Sarika U Peters; Alan K Percy; Daniel G Glaze
Journal:  Pediatr Neurol       Date:  2021-07-24       Impact factor: 4.210

8.  Developmental Skills of Individuals with Angelman Syndrome Assessed Using the Bayley-III.

Authors:  Anjali Sadhwani; Anne Wheeler; Lynne M Bird; Wen-Hann Tan; Angela Gwaltney; Sarika U Peters; Rene L Barbieri-Welge; Lucia T Horowitz; Lisa M Noll; Rachel J Hundley
Journal:  J Autism Dev Disord       Date:  2021-01-30

9.  Angelman Syndrome: A Case Report.

Authors:  Farah Ashrafzadeh; Arianeh Sadrnabavi; Javad Akhondian; Mehran Beiraghi Toosi; Mohammadhassan Mohammadi; Kazem Hassanpour
Journal:  Iran J Child Neurol       Date:  2016

10.  Delta power robustly predicts cognitive function in Angelman syndrome.

Authors:  Lauren M Ostrowski; Elizabeth R Spencer; Lynne M Bird; Ronald Thibert; Robert W Komorowski; Mark A Kramer; Catherine J Chu
Journal:  Ann Clin Transl Neurol       Date:  2021-05-28       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.